113 Results for "

human PD-L1

" in MedChemExpress (MCE) Product Catalog:
Products (113)

113 Results for "human PD-L1" in MCE Product Catalog:

26
26 Publications Verification
Cat. No.: HY-19745
CAS No.: 1675203-84-5
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity .
loading...
    loading...
26
26 Publications Verification
Cat. No.: HY-19745B
CAS No.: 2089334-95-0
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-P9903
CAS No.: 946414-94-4
Synonyms: BMS-936558; ONO-4538; MDX-1106

Target:  

PD-1/PD-L1

Research Areas:  

Infection Cancer

Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730
CAS No.: 1537032-82-8
Synonyms: Anti-human PD-L1, human Antibody; MSB 0010718C; MSB0010718C

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730A
CAS No.: 1537032-82-8
Purity:  96.02%

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P73361
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD274; B7 Homolog 1; Prev. PDCD1LG1; B7-H; PD-L1; PDCD1 Ligand 1; B7H1; PDCD1L1; PDL1; HPD-L1; Programmed Cell Death 1 Ligand 1; Programmed Death Ligand 1; CD274 Antigen; ADMIO5; CD274 Molecule; B7-H1
Species:  
Source:  
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P9919
CAS No.: 1428935-60-7
Synonyms: MEDI 4736

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P9919A
CAS No.: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P990173

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-134884
CAS No.: 2230911-59-6
Purity:  99.80%
Synonyms: PD-1/PD-L1-IN-8
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99100
CAS No.: 2556646-63-8
Synonyms: CTL-002

Research Areas:  

Cancer

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P7397
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD274; B7 Homolog 1; Prev. PDCD1LG1; B7-H; PD-L1; PDCD1 Ligand 1; B7H1; PDCD1L1; PDL1; HPD-L1; Programmed Cell Death 1 Ligand 1; Programmed Death Ligand 1; CD274 Antigen; ADMIO5; CD274 Molecule; B7-H1
Species:  
Source:  
CHO
loading...
    loading...
Cat. No.: HY-P99115
CAS No.: 2102192-68-5
Synonyms: ASC 22; KN 035

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
loading...
    loading...
Cat. No.: HY-177439
Research Areas:  

Cancer

HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .
loading...
    loading...
Cat. No.: HY-P10375
CAS No.: 1629665-96-8
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 .
loading...
    loading...
Cat. No.: HY-P99457
CAS No.: 2148321-77-9
Synonyms: AGEN2034

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .
loading...
    loading...
Cat. No.: HY-138407
CAS No.: 2374856-75-2
Purity:  98.14%
Synonyms: GS-4224; PD-1/PD-L1-IN 7
Target:  

PD-1/PD-L1 HBV

Research Areas:  

Infection Cancer

Evixapodlin (GS-4224) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. Evixapodlin has anticancer and antiviral functions .
loading...
    loading...
Cat. No.: HY-P99618
CAS No.: 2377419-89-9
Synonyms: IBI-315; BH2950

Target:  

EGFR PD-1/PD-L1

Research Areas:  

Cancer

Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .
loading...
    loading...
Cat. No.: HY-P99345
CAS No.: 2022215-59-2
Synonyms: TSR-042; ANB-011; WBP-285

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
loading...
    loading...
Cat. No.: HY-P3139
CAS No.: 2426685-25-6
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .
loading...
    loading...